Analysts think IBRX stock price could increase by 52%
Feb 09, 2026, 12:25 PM
65.15%
What does IBRX do
ImmunityBio is a San Diego-based clinical stage immunotherapy company with 628 employees, focusing on therapies for urologic cancers and infectious diseases. Its lead product candidate, Anktiva, is an IL-15 superagonist fusion protein.
7 analysts think IBRX stock price will increase by 51.61%. The current median analyst target is $9.18 compared to a current stock price of $6.05. The lowest analysts target is $7.07 and the highest analyst target is $25.20.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.